Drugs / TAK-164
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | cervical adenosquamous carcinoma, glassy cell variant | 2018-02-09 | “Received notice that partner Takeda has filed an IND for TAK-164, an ADC directed to GCC-positive tumors using ImmunoGen’s IGN platform.” abbvie.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03449030 | Apr 2018 → Feb 2020 | digestive system cancer | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03449030 ↗ |
| Action | Deplete | “We demonstrate TAK-164 selectively binds to, is internalized by, and has potent cytotoxic effects against GCC-expressing cells in vitro” PMID 32788205 ↗ Aug 2020 |
| Modality | Other / unclassified | “The drug being tested in this study is a novel antibody-drug conjugate (ADC) called TAK-164.” NCT03449030 ↗ |
| Route | Intravenous | “received intravenous TAK-164 on day 1 of 21-day cycles” PMID 36738333 ↗ Feb 2023 |